RENAU.UNSP.ARD 1/5 EO-20 (56S0) - Net Assets
Based on the latest financial reports, RENAU.UNSP.ARD 1/5 EO-20 (56S0) has net assets worth €4.14 Billion EUR (≈ $4.84 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€8.19 Billion ≈ $9.57 Billion USD) and total liabilities (€4.05 Billion ≈ $4.73 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 56S0 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.14 Billion |
| % of Total Assets | 50.59% |
| Annual Growth Rate | 17.95% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 21.76 |
RENAU.UNSP.ARD 1/5 EO-20 - Net Assets Trend (2022–2025)
This chart illustrates how RENAU.UNSP.ARD 1/5 EO-20's net assets have evolved over time, based on quarterly financial data. See 56S0 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for RENAU.UNSP.ARD 1/5 EO-20 (2022–2025)
The table below shows the annual net assets of RENAU.UNSP.ARD 1/5 EO-20 from 2022 to 2025. For live valuation and market cap data, see RENAU.UNSP.ARD 1/5 EO-20 (56S0) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
+2.54% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
+50.49% |
| 2023-12-31 | €2.67 Billion ≈ $3.13 Billion |
+6.35% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to RENAU.UNSP.ARD 1/5 EO-20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 20.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.65 Billion | 64.71% |
| Other Components | €1.44 Billion | 35.29% |
| Total Equity | €4.09 Billion | 100.00% |
RENAU.UNSP.ARD 1/5 EO-20 Competitors by Market Cap
The table below lists competitors of RENAU.UNSP.ARD 1/5 EO-20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
YANGTZE OPT.FIB.AND CAB.H
F:1YO
|
$15.48 Billion |
|
PTT Exploration and Production Public Company Limited
F:NVAL
|
$15.48 Billion |
|
Hua Xia Bank Co Ltd
SHG:600015
|
$15.49 Billion |
|
Banco Santander Chile
SN:BSANTANDER
|
$15.49 Billion |
|
China International Capital Corp Ltd
SHG:601995
|
$15.47 Billion |
|
Taiwan Union Technology
TWO:6274
|
$15.46 Billion |
|
Jde Peets Nv
AS:JDEP
|
$15.46 Billion |
|
Power Finance Corporation Limited
NSE:PFC
|
$15.44 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RENAU.UNSP.ARD 1/5 EO-20's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,986,600,000 to 4,090,500,000, a change of 103,900,000 (2.6%).
- Net income of 265,600,000 contributed positively to equity growth.
- Dividend payments of 67,100,000 reduced retained earnings.
- New share issuances of 200,000 increased equity.
- Other factors decreased equity by 94,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €265.60 Million | +6.49% |
| Dividends Paid | €67.10 Million | -1.64% |
| Share Issuances | €200.00K | +0.0% |
| Other Changes | €-94.80 Million | -2.32% |
| Total Change | €- | 2.61% |
Book Value vs Market Value Analysis
This analysis compares RENAU.UNSP.ARD 1/5 EO-20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.38x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.60x to 0.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €26.57 | €15.90 | x |
| 2023-12-31 | €28.63 | €15.90 | x |
| 2024-12-31 | €40.97 | €15.90 | x |
| 2025-12-31 | €42.04 | €15.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RENAU.UNSP.ARD 1/5 EO-20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.49%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.95%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.95x
- Recent ROE (6.49%) is below the historical average (14.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 35.77% | 25.08% | 0.69x | 2.07x | €631.17 Million |
| 2023 | 11.76% | 11.18% | 0.36x | 2.93x | €46.45 Million |
| 2024 | 4.39% | 6.30% | 0.34x | 2.07x | €-223.56 Million |
| 2025 | 6.49% | 8.95% | 0.37x | 1.95x | €-143.45 Million |
Industry Comparison
This section compares RENAU.UNSP.ARD 1/5 EO-20's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $7,097,803,995
- Average return on equity (ROE) among peers: -7.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | €4.14 Billion | 35.77% | 0.98x | $15.47 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $2.39 Billion |
| MEDIMI AB AK (79T) | $15.24 Million | -107.34% | 0.16x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $1.40 Billion | 8.39% | 0.66x | $929.85 Million |
| Carl Zeiss Meditec AG (AFX) | $1.42 Billion | 11.27% | 0.43x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.03 Billion | 14.48% | 0.39x | $2.14 Billion |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $6.75 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $17.30 Billion | 27.65% | 1.78x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $78.07 Billion |
About RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more